Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Bruce G. Robinson(The University of Sydney), Robert I. Haddad(Georgetown University), Luis Paz‐Ares(Universidad Complutense de Madrid), Annetta Krebs(The University of Texas MD Anderson Cancer Center), James R. Vasselli(The University of Texas MD Anderson Cancer Center)
Cited by 255
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926